Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 2 (2005), Issue 8 (August)

1. Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?
   Nat Rev Drug Discov, 4(8): 639-47. [Abstract] [Full-text]
2. Treatment of menopausal symptoms: what shall we do now?
   Lancet, 366(9483): 409-21. [Abstract] [Full-text]
3. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.
   Lancet, 366(9483): 378-84. [Abstract] [Full-text]
4. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
   Lancet Oncol, 6(8): 581-8. [Abstract] [Full-text]
5. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children.
   Lancet Oncol, 6(8): 573-80. [Abstract] [Full-text]
6. Validation of a method for localised microinjection of drugs into thalamic subregions in rats for epilepsy pharmacological studies.
   J Neurosci Methods, 146(2): 191-7. [Abstract] [Full-text]
7. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study).
   J Am Coll Cardiol, 46(3): 417-24. [Abstract] [Full-text]
8. Retrospective analysis of suspending HAART in selected patients with controlled HIV replication.
   AIDS Patient Care STDS, 19(7): 429-38. [Abstract] [Full-text]
9. Structured intermittent therapy with seven-day cycles of HAART for chronic HIV infection: a pilot study in São Paulo, Brazil.
   AIDS Patient Care STDS, 19(7): 425-8. [Abstract] [Full-text]
10. Toward the next-generation drug delivery vehicle: synthesis of a dendrimer with four orthogonally reactive groups.
    Mol Pharm, 2(4): 273-7. [Abstract] [Full-text]
11. Dendrimeric micelles for controlled drug release and targeted delivery.
    Mol Pharm, 2(4): 264-72. [Abstract] [Full-text]
12. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
    Biochem Pharmacol, 70(5): 658-67. [Abstract] [Full-text]
13. Improving delivery of hydrophobic drugs from hydrogels through cyclodextrins.
    J Biomed Mater Res A, 74(3): 454-60. [Abstract] [Full-text]
14. An exploration into the most effective way to teach drug calculation skills to nursing students.
    Nurse Educ Today, 25(6): 430-6. [Abstract] [Full-text]
15. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies.
    Bone Marrow Transplant, 36(4): 349-54. [Abstract] [Full-text]
16. Determinants of prescribing of second-choice antibiotics for upper and lower respiratory tract episodes in Dutch general practice.
    J Antimicrob Chemother, 56(2): 420-2. [Abstract] [Full-text]
17. Why has oral rehydration for calves and children diverged: direct vs. indirect criteria of efficacy.
    Res Vet Sci, 79(3): 177-81. [Abstract] [Full-text]
18. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus.
    Arch Pediatr Adolesc Med, 159(8): 764-70. [Abstract] [Full-text]
19. Suicide risk in patients treated with lithium.
    Arch Gen Psychiatry, 62(8): 860-6. [Abstract] [Full-text]
20. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer.
    Cancer Res, 65(15): 7000-6. [Abstract] [Full-text]
21. It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.
    Cancer Res, 65(15): 6957-66. [Abstract] [Full-text]
22. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
    Cancer Res, 65(15): 6943-9. [Abstract] [Full-text]
23. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.
    Cancer Res, 65(15): 6934-42. [Abstract] [Full-text]
24. Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring.
    Cancer Res, 65(15): 6858-63. [Abstract] [Full-text]
25. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.
    Cancer Res, 65(15): 6850-7. [Abstract] [Full-text]
26. Progressive neuropsychiatric problems following institution of highly active antiretroviral therapy.
    Sex Transm Infect, 81(4): 351-7. [Abstract] [Full-text]
27. Sex and relationships for HIV positive women since HAART: a quantitative study.
    Sex Transm Infect, 81(4): 333-7. [Abstract] [Full-text]
28. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study.
    Bone Marrow Transplant, 36(2): 163-9. [Abstract] [Full-text]
29. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.
    Leukemia, 19(7): 1198-206. [Abstract] [Full-text]
30. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
    Leukemia, 19(7): 1161-8. [Abstract] [Full-text]
31. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.
    Leukemia, 19(7): 1184-91. [Abstract] [Full-text]
32. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
    Leukemia, 19(7): 1207-10. [Abstract] [Full-text]
33. Loss of E-cadherin mediated cell-cell adhesion as an early trigger of apoptosis induced by photodynamic treatment.
    J Cell Physiol, 205(1): 86-96. [Abstract] [Full-text]
34. Structure-release rate correlation in collagen gels containing fluorescent drug analog.
    Biomaterials, 26(34): 7164-72. [Abstract] [Full-text]
35. Sol-gel synthesis of a multifunctional, hierarchically porous silica/apatite composite.
    Biomaterials, 26(34): 6827-35. [Abstract] [Full-text]
36. Inhibition of implant-associated infections via nitric oxide release.
    Biomaterials, 26(34): 6984-90. [Abstract] [Full-text]
37. Interaction between O-carboxymethylchitosan and dipalmitoyl-sn-glycero-3-phosphocholine bilayer.
    Biomaterials, 26(34): 6873-9. [Abstract] [Full-text]
38. Liquid filled nanoparticles as a drug delivery tool for protein therapeutics.
    Biomaterials, 26(34): 7154-63. [Abstract] [Full-text]
39. Chlorhexidine-releasing methacrylate dental composite materials.
    Biomaterials, 26(34): 7145-53. [Abstract] [Full-text]
40. In vitro characterization of leukocyte mimetic for targeting therapeutics to the endothelium using two receptors.
    Biomaterials, 26(34): 7136-44. [Abstract] [Full-text]
41. Design, synthesis, and evaluation of original carriers for targeting vascular endothelial growth factor receptor interactions.
    Pharm Res, 22(8): 1411-21. [Abstract] [Full-text]
42. Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model.
    Pharm Res, 22(8): 1320-30. [Abstract] [Full-text]
43. A novel in vitro and numerical analysis of shear-induced drug release from extended-release tablets in the fed stomach.
    Pharm Res, 22(8): 1215-26. [Abstract] [Full-text]
44. Ultrastructural acute features of active remodeling after chemical pleurodesis induced by silver nitrate or talc.
    Lung, 183(3): 197-207. [Abstract] [Full-text]
45. Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer.
    Lung, 183(3): 177-83. [Abstract] [Full-text]
46. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.
    J Natl Cancer Inst, 97(15): 1137-42. [Abstract] [Full-text]
47. Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: a phase II study.
    Acta Oncol, 44(3): 248-54. [Abstract] [Full-text]
48. Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
    Acta Oncol, 44(3): 230-5. [Abstract] [Full-text]
49. High-dose radiotherapy and concurrent UFT plus l-leucovorin in locally advanced rectal cancer: a phase I trial.
    Acta Oncol, 44(3): 224-9. [Abstract] [Full-text]
50. Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus.
    Int J Cancer, 116(6): 903-8. [Abstract] [Full-text]
51. The class effect: is it relevant to geriatrics?
    J Am Geriatr Soc, 53(8): 1402-4. [Abstract] [Full-text]
52. Potentially inappropriate prescribing in elderly veterans: are we using the wrong drug, wrong dose, or wrong duration?
    J Am Geriatr Soc, 53(8): 1282-9. [Abstract] [Full-text]
53. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison.
    Br J Cancer, 93(3): 279-86. [Abstract] [Full-text]
54. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.
    Blood, 106(4): 1473-8. [Abstract] [Full-text]
55. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach.
    Blood, 106(4): 1164-74. [Abstract] [Full-text]
56. Patterns of clinical use of antipsychotics in hospitalized psychiatric patients.
    Prog Neuropsychopharmacol Biol Psychiatry, 29(6): 957-63. [Abstract] [Full-text]
57. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.
    Nat Biotechnol, 23(8): 1002-7. [Abstract] [Full-text]
58. Investigation of multidrug resistance in cultured human renal cell carcinoma cells by 31P-NMR spectroscopy and treatment survival assays.
    MAGMA, 18(3): 144-61. [Abstract] [Full-text]
59. New drug targets in the signaling pathways activated by antidepressants.
    Prog Neuropsychopharmacol Biol Psychiatry, 29(6): 1010-6. [Abstract] [Full-text]
60. Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines.
    Breast, 14(4): 304-9. [Abstract] [Full-text]
61. Measures of adherence based on self-report exhibited poor agreement with those based on pharmacy records.
    J Clin Epidemiol, 58(9): 924-33. [Abstract] [Full-text]
62. Prevention of neonatal sepsis.
    Clin Perinatol, 32(3): 601-15. [Abstract] [Full-text]
63. MR-guided percutaneous sclerotherapy of low-flow vascular malformations in the head and neck.
    Magn Reson Imaging Clin N Am, 13(3): 595-600. [Abstract] [Full-text]
64. Do drug samples influence resident prescribing behavior? A randomized trial.
    Am J Med, 118(8): 881-4. [Abstract] [Full-text]
65. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
    Cancer, 104(4): 841-7. [Abstract] [Full-text]
66. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
    Cancer, 104(4): 676-81. [Abstract] [Full-text]
67. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
    Cancer, 104(4): 864-8. [Abstract] [Full-text]
68. Nicotine use in schizophrenia: the self medication hypotheses.
    Neurosci Biobehav Rev, 29(6): 1021-34. [Abstract] [Full-text]
69. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer.
    J Steroid Biochem Mol Biol, 96(2): 95-108. [Abstract] [Full-text]
70. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk.
    J Infect Dis, 192(5): 713-9. [Abstract] [Full-text]
71. Radiofrequency versus injection snoreplasty in simple snoring.
    Otolaryngol Head Neck Surg, 133(2): 224-8. [Abstract] [Full-text]
72. Bilateral sequential photodynamic therapy for sub-retinal neovascularization with type 2A parafoveal telangiectasis.
    Am J Ophthalmol, 140(2): 333-5. [Abstract] [Full-text]
73. Photodynamic therapy for choroidal neovascularization on late-onset fundus flavimaculatus.
    Am J Ophthalmol, 140(2): 312-4. [Abstract] [Full-text]
74. Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial.
    Radiother Oncol, 75(2): 193-6. [Abstract] [Full-text]
75. Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma.
    Oncology, 68(2): 239-45. [Abstract] [Full-text]
76. Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study.
    Oncology, 68(2): 223-9. [Abstract] [Full-text]
77. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
    Oncology, 68(2): 212-6. [Abstract] [Full-text]
78. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.
    Oncology, 68(2): 190-5. [Abstract] [Full-text]
79. Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma.
    Oncology, 68(2): 146-53. [Abstract] [Full-text]
80. Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts.
    Oncology, 68(2): 130-7. [Abstract] [Full-text]
81. Specificity of female and male sex hormones on excitatory and inhibitory phases of formalin-induced nociceptive responses.
    Brain Res, 1052(1): 105-11. [Abstract] [Full-text]
82. Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?
    Oncology, 68(2): 115-21. [Abstract] [Full-text]
83. The use of pethidine as pre-medication to prevent anoxic spells in patients with tetralogy of Fallot.
    Pediatr Int, 47(4): 388-91. [Abstract] [Full-text]
84. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma.
    Value Health, 8(4): 462-70. [Abstract] [Full-text]
85. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?
    Value Health, 8(4): 433-46. [Abstract] [Full-text]
86. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women.
    Hum Reprod, 20(9): 2653-60. [Abstract] [Full-text]
87. Spatial memory in middle-aged female rats: assessment of estrogen replacement after ovariectomy.
    Brain Res, 1052(2): 163-73. [Abstract] [Full-text]
88. Case study: contrasting challenges of insulin pump therapy in a toddler and adolescent with type 1 diabetes.
    Diabetes Educ, 31(4): 584-90. [Abstract] [Full-text]
89. Efficacy of ultrasound in the diagnosis of pleurodesis in rabbits.
    Chest, 128(2): 934-9. [Abstract] [Full-text]
90. Stroke volume and pulse pressure variation for prediction of fluid responsiveness in patients undergoing off-pump coronary artery bypass grafting.
    Chest, 128(2): 848-54. [Abstract] [Full-text]
91. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions.
    Chest, 128(2): 684-9. [Abstract] [Full-text]
92. Assessment of the understanding of the risks and benefits of hormone replacement therapy (HRT) in primary care physicians.
    Am J Obstet Gynecol, 193(2): 551-6; discussion 556-8. [Abstract] [Full-text]
93. Early prognostic usefulness of C-reactive protein added to the Thrombolysis In Myocardial Infarction risk score in acute coronary syndromes.
    Am J Cardiol, 96(4): 533-7. [Abstract] [Full-text]
94. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
    Br J Haematol, 130(4): 588-94. [Abstract] [Full-text]
95. Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma.
    Br J Haematol, 130(4): 536-41. [Abstract] [Full-text]
96. Philadelphia positive acute lymphoblastic leukaemia of childhood.
    Br J Haematol, 130(4): 489-500. [Abstract] [Full-text]
97. Continuing challenges in childhood non-Hodgkin's lymphoma.
    Br J Haematol, 130(4): 480-8. [Abstract] [Full-text]
98. Selective photothermolysis of blood vessels following flashlamp-pumped pulsed dye laser irradiation: in vivo results and mathematical modelling are in agreement.
    J Invest Dermatol, 125(2): 343-52. [Abstract] [Full-text]
99. Slow internal release of bioactive compounds under the effect of skin enzymes.
    J Invest Dermatol, 125(2): 270-7. [Abstract] [Full-text]
100. HRT and breast cancer: impact on population risk and incidence.
     Eur J Cancer, 41(12): 1775-81. [Abstract] [Full-text]
101. Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma.
     Eur J Cancer, 41(12): 1739-45. [Abstract] [Full-text]
102. Preoperative oral antibiotics in colorectal surgery increase the rate of Clostridium difficile colitis.
     Arch Surg, 140(8): 752-6. [Abstract] [Full-text]
103. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
     Cancer Res, 65(16): 7429-35. [Abstract] [Full-text]
104. Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models.
     Cancer Res, 65(16): 7186-93. [Abstract] [Full-text]
105. New entrants to HIV care are presenting only at marginally earlier stages of disease but may increasingly represent groups perceived at lower risk.
     J Int Assoc Physicians AIDS Care (Chic Ill), 4(2): 47-51. [Abstract] [Full-text]
106. Plant lectins as carriers for oral drugs: is wheat germ agglutinin a suitable candidate?
     Toxicol Appl Pharmacol, 207(2): 170-8. [Abstract] [Full-text]
107. How graduate nurses use protocols to manage patients' medications.
     J Clin Nurs, 14(8): 935-44. [Abstract] [Full-text]
108. Comparative study between the effects of photodynamic therapy and conventional therapy on microbial reduction in ligature-induced peri-implantitis in dogs.
     J Periodontol, 76(8): 1275-81. [Abstract] [Full-text]
109. Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro.
     Oncology, 68(4): 538-47. [Abstract] [Full-text]
110. Phase II study of an 'all-oral' regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer--safety, efficacy and quality of life.
     Oncology, 68(4): 520-5. [Abstract] [Full-text]
111. Biological evaluation of calcium alginate microspheres as a vehicle for the localized delivery of a therapeutic enzyme.
     J Biomed Mater Res A, 74(4): 545-52. [Abstract] [Full-text]
112. Indomethacin-loaded methoxy poly(ethylene glycol)/poly(D,L-lactide) amphiphilic diblock copolymeric nanospheres: pharmacokinetic and toxicity studies in rodents.
     J Biomed Mater Res A, 74(4): 581-90. [Abstract] [Full-text]
113. Vinylpyrrolidone-co-(meth)acrylic acid inserts for ocular drug delivery: synthesis and evaluation.
     J Biomed Mater Res A, 74(4): 598-606. [Abstract] [Full-text]
114. Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer.
     Oncology, 68(4): 485-92. [Abstract] [Full-text]
115. A phase I study of docetaxel, Cisplatin, 5-Fluorouracil and leucovorin.
     Oncology, 68(4): 479-84. [Abstract] [Full-text]
116. Dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer.
     Oncology, 68(4): 446-53. [Abstract] [Full-text]
117. Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
     Oncology, 68(4): 438-45. [Abstract] [Full-text]
118. Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients.
     Oncology, 68(4): 432-7. [Abstract] [Full-text]
119. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma.
     Oncology, 68(4): 422-31. [Abstract] [Full-text]
120. Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.
     Oncology, 68(4): 391-7. [Abstract] [Full-text]
121. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
     Oncology, 68(4): 382-90. [Abstract] [Full-text]
122. Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.
     Oncology, 68(4): 350-5. [Abstract] [Full-text]
123. A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.
     Oncology, 68(4): 333-40. [Abstract] [Full-text]
124. Outcomes of inappropriate prescribing of beta-blockers after an acute myocardial infarction in a Medicaid population.
     Ann Pharmacother, 39(9): 1416-22. [Abstract] [Full-text]
125. Vancomycin release behaviour from amorphous calcium polyphosphate matrices intended for osteomyelitis treatment.
     Biomaterials, 26(35): 7276-85. [Abstract] [Full-text]
126. Therapeutic potential of nanoparticulate systems for macrophage targeting.
     Biomaterials, 26(35): 7260-75. [Abstract] [Full-text]
127. Impact of heat on nanocrystalline silver dressings. Part II: Physical properties.
     Biomaterials, 26(35): 7230-40. [Abstract] [Full-text]
128. Impact of heat on nanocrystalline silver dressings. Part I: Chemical and biological properties.
     Biomaterials, 26(35): 7221-9. [Abstract] [Full-text]
129. Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution.
     Biomaterials, 26(35): 7251-9. [Abstract] [Full-text]
130. Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours.
     Br J Cancer, 93(4): 412-7. [Abstract] [Full-text]
131. Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study.
     Br J Cancer, 93(4): 392-8. [Abstract] [Full-text]
132. Explaining black-white differences in receipt of recommended colon cancer treatment.
     J Natl Cancer Inst, 97(16): 1211-20. [Abstract] [Full-text]
133. Relationship between time of day, day of week, timeliness of reperfusion, and in-hospital mortality for patients with acute ST-segment elevation myocardial infarction.
     JAMA, 294(7): 803-12. [Abstract] [Full-text]
134. Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers.
     Am J Surg, 190(3): 371-5. [Abstract] [Full-text]
135. FFPRHC Guidance (July 2005): The use of contraception outside the terms of the product licence.
     J Fam Plann Reprod Health Care, 31(3): 225-41; quiz 242. [Abstract] [Full-text]
136. Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
     BJU Int, 96(4): 640-6. [Abstract] [Full-text]
137. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction.
     Proc Natl Acad Sci U S A, 102(33): 11600-5. [Abstract] [Full-text]
138. Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.
     Br J Cancer, 93(4): 406-11. [Abstract] [Full-text]
139. Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
     J Clin Oncol, 23(24): 5774-8. [Abstract] [Full-text]
140. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
     J Clin Oncol, 23(24): 5705-17. [Abstract] [Full-text]
141. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
     J Clin Oncol, 23(24): 5696-704. [Abstract] [Full-text]
142. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
     J Clin Oncol, 23(24): 5660-7. [Abstract] [Full-text]
143. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
     J Clin Oncol, 23(24): 5613-9. [Abstract] [Full-text]
144. In vitro sustained human transscleral drug delivery of fluorescein-labeled dexamethasone and methotrexate with fibrin sealant.
     Curr Eye Res, 30(8): 653-60. [Abstract] [Full-text]
145. Management of gastric lymphoma with chemotherapy alone.
     Leuk Lymphoma, 46(9): 1329-35. [Abstract] [Full-text]
146. Primary breast lymphoma: outcome of 7 patients and a review of the literature.
     Leuk Lymphoma, 46(9): 1321-7. [Abstract] [Full-text]
147. Impaired vision and the ability to take medications.
     J Am Geriatr Soc, 53(7): 1179-90. [Abstract] [Full-text]
148. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count.
     Am J Epidemiol, 162(5): 471-8. [Abstract] [Full-text]
149. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.
     Am J Epidemiol, 162(5): 404-14. [Abstract] [Full-text]
150. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.
     J Clin Oncol, 23(24): 5620-7. [Abstract] [Full-text]
151. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
     J Clin Oncol, 23(24): 5568-77. [Abstract] [Full-text]
152. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
     J Clin Oncol, 23(24): 5578-87. [Abstract] [Full-text]
153. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
     J Clin Oncol, 23(24): 5728-38. [Abstract] [Full-text]
154. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
     J Clin Oncol, 23(24): 5739-45. [Abstract] [Full-text]
155. Ultrasound thrombolysis.
     Thromb Haemost, 94(1): 26-36. [Abstract] [Full-text]
156. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study.
     Thromb Haemost, 94(1): 17-25. [Abstract] [Full-text]
157. Optical coherence tomography guided retreatment of photodynamic therapy.
     Br J Ophthalmol, 89(9): 1184-7. [Abstract] [Full-text]
158. Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation.
     Br J Ophthalmol, 89(9): 1109-11. [Abstract] [Full-text]
159. Best evidence topic report. Are antibiotics indicated following human bites?
     Emerg Med J, 22(9): 654. [Abstract] [Full-text]
160. Simplifying thrombolysis decisions in patients with left bundle branch block.
     Emerg Med J, 22(9): 617-20. [Abstract] [Full-text]
161. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study.
     Lancet, 366(9486): 635-42. [Abstract] [Full-text]
162. A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.
     Int J Radiat Oncol Biol Phys, 63(1): 188-93. [Abstract] [Full-text]
163. A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases.
     Protein Eng Des Sel, 18(9): 417-24. [Abstract] [Full-text]
164. Treatment of cryptosporidiosis in immunocompromised hosts.
     Chemotherapy, 51(4): 193-6. [Abstract] [Full-text]
165. Antibiotic use following a Korean national policy to prohibit medication dispensing by physicians.
     Health Policy Plan, 20(5): 302-9. [Abstract] [Full-text]
166. Precipitation casting of drug-loaded microporous PCL matrices: incorporation of progesterone by co-dissolution.
     J Control Release, 106(3): 263-72. [Abstract] [Full-text]
167. Does Hypericum perforatum L. extract show any specificity as photosensitizer for HL-60 leukemic cells and cord blood hemopoietic progenitors during photodynamic therapy?
     J Photochem Photobiol B, 80(3): 208-16. [Abstract] [Full-text]
168. Sensitivity to ALA-PDT of cell lines with different nitric oxide production and resistance to NO cytotoxicity.
     J Photochem Photobiol B, 80(3): 195-202. [Abstract] [Full-text]
169. Lipid cubic phases for improved topical drug delivery in photodynamic therapy.
     J Control Release, 106(3): 350-60. [Abstract] [Full-text]
170. Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia.
     Blood, 106(5): 1749-54. [Abstract] [Full-text]
171. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
     Blood, 106(5): 1538-43. [Abstract] [Full-text]
172. Development of polyethylene glycol-conjugated poly-S-nitrosated serum albumin, a novel S-Nitrosothiol for prolonged delivery of nitric oxide in the blood circulation in vivo.
     J Pharmacol Exp Ther, 314(3): 1117-24. [Abstract] [Full-text]
173. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.
     Blood, 106(5): 1867-74. [Abstract] [Full-text]
174. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.
     Blood, 106(5): 1839-42. [Abstract] [Full-text]
175. A positive outcome in patient with massive acute pulmonary embolism and right atrial mobile thrombus fragmented during thrombolysis: a serial echocardiographic examination.
     J Intern Med, 258(3): 281-4. [Abstract] [Full-text]
176. Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children.
     Br J Haematol, 130(5): 781-7. [Abstract] [Full-text]
177. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
     Br J Haematol, 130(5): 691-9. [Abstract] [Full-text]
178. Menopausal symptom management and prevention counseling after the Women's Health Initiative among women seen in an internal medicine practice.
     J Womens Health (Larchmt), 14(6): 507-14. [Abstract] [Full-text]
179. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases.
     Br J Surg, 92(9): 1155-60. [Abstract] [Full-text]
180. Identification and functional characterization of riboflavin transporter in human-derived retinoblastoma cell line (Y-79): mechanisms of cellular uptake and translocation.
     J Ocul Pharmacol Ther, 21(4): 275-87. [Abstract] [Full-text]
181. Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.
     Oncology, 69(1): 88-95. [Abstract] [Full-text]
182. Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities.
     Oncology, 69(1): 81-7. [Abstract] [Full-text]
183. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
     Oncology, 69(1): 63-70. [Abstract] [Full-text]
184. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.
     Oncology, 69(1): 27-34. [Abstract] [Full-text]
185. Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
     Oncology, 69(1): 19-26. [Abstract] [Full-text]
186. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
     Leukemia, 19(9): 1509-16. [Abstract] [Full-text]
187. Molecular mechanisms in the pathogenesis and treatment of acute ischemic stroke.
     J Invest Surg, 18(4): 207-18. [Abstract] [Full-text]
188. Endovascular management of acute deep vein thrombosis.
     Am J Med, 118: 31S-36S. [Abstract] [Full-text]
189. Breast conservation after neoadjuvant chemotherapy for stage II carcinoma of the breast.
     J Am Coll Surg, 201(3): 327-34. [Abstract] [Full-text]
190. AIDS-related progressive multifocal leukoencephalopathy in the era of HAART: report of two cases and review of the literature.
     AIDS Patient Care STDS, 19(8): 486-94. [Abstract] [Full-text]
191. Simulation of gentamicin delivery for the local treatment of osteomyelitis.
     Biotechnol Bioeng, 91(5): 622-35. [Abstract] [Full-text]
192. Outcome after the introduction of a multimodality treatment program for locally advanced rectal cancer.
     Eur J Surg Oncol, 31(7): 727-34. [Abstract] [Full-text]
193. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART).
     Muscle Nerve, 32(3): 247-60. [Abstract] [Full-text]
194. Frequency, type and clinical importance of medication history errors at admission to hospital: a systematic review.
     CMAJ, 173(5): 510-5. [Abstract] [Full-text]
195. Bacterial contaminants and antibiotic prophylaxis in total hip arthroplasty.
     J Bone Joint Surg Br, 87(9): 1256-8. [Abstract] [Full-text]
196. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
     Lancet Oncol, 6(9): 649-58. [Abstract] [Full-text]
197. Toxic keratopathy-related corneal dehydration after laser in situ keratomileusis.
     J Cataract Refract Surg, 31(8): 1656-8. [Abstract] [Full-text]
198. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters.
     J Med Virol, 77(2): 164-72. [Abstract] [Full-text]
199. Bridging advanced glycation end product, receptor for advanced glycation end product and nitric oxide with hormonal replacement/estrogen therapy in healthy versus diabetic postmenopausal women: a perspective.
     Biochim Biophys Acta, 1745(2): 145-55. [Abstract] [Full-text]
200. Targeting drugs to combinations of receptors: a modeling analysis of potential specificity.
     Ann Biomed Eng, 33(8): 1113-24. [Abstract] [Full-text]
201. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART.
     AIDS Res Hum Retroviruses, 21(8): 706-13. [Abstract] [Full-text]
202. Short communication: HIV infection, antiretrovirals, and apoptosis: studies on skeletal muscle.
     AIDS Res Hum Retroviruses, 21(8): 702-5. [Abstract] [Full-text]
203. In vitro release of clomipramine HCl and buprenorphine HCl from poly adipic anhydride (PAA) and poly trimethylene carbonate (PTMC) blends.
     J Biomed Mater Res A, 75(1): 185-91. [Abstract] [Full-text]
204. Pediatric renal tumors: practical updates for the pathologist.
     Pediatr Dev Pathol, 8(3): 320-38. [Abstract] [Full-text]
205. Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy.
     Neuroradiology, 47(8): 616-21. [Abstract] [Full-text]
206. Cell-penetrating peptides: tools for intracellular delivery of therapeutics.
     Cell Mol Life Sci, 62(16): 1839-49. [Abstract] [Full-text]
207. A preliminary report on patient acceptance of a novel intra-oral lubricating device for the management of radiotherapy-related xerostomia.
     Clin Oral Investig, 9(3): 148-53. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.